NICE, France--(BUSINESS WIRE)--June 16, 2006--Dual chamber implantable cardioverter-defibrillators (DC ICDs) showed greater efficacy in reducing clinically significant adverse events compared to single chamber (SC) ICDs for patients with a standard ICD indication, according to data presented today. ICDs represent an appropriate therapy option for the hundreds of thousands of patients at risk of sudden cardiac death worldwide every year.(1)(2)(3) The results of the DATAS clinical trial, presented at Cardiostim 2006, the 15th World Congress in Cardiac Electrophysiology and Cardiac Techniques, showed that clinically significant adverse events can be reduced by one-third with DC ICDs compared to SC ICDs in patients at risk of sudden cardiac death.(1)
